Biotech Daily

Wednesday August 13, 2025

Daily news on ASX-listed biotechnology companies

*** ASX DOWN, BIOTECH EVEN, BIG CAPS MIXED**

*** STARPHARMA UP 26%; UNIVERSAL BIOSENSORS DOWN 12.5%**

*** AVITA RAISES $22.7m**

*** ATOMO PLACES $417k SHARE PLAN SHORTFALL; TOTAL $3.1m**

*** ORTHOCELL 10 US REMPLIR SURGERIES**

*** VITASORA EXPANDS CHRONIC CARE, REMOTE MONITORING**

*** IMAGION, WAYNE STATE UNI TO DEVELOP MAGSENSE A.I. FOR CANCER**

*** LUMOS ASX LISTING RULE 10.1 WAIVER FOR $5m LOAN**

*** FIREBRICK: EU ACCEPTS NASODINE COVID-19 PATENT**

*** NYRADA APPOINTS PROF WILLIAM CHAN CARDIAC TRIAL CONSULTANT**

MARKET REPORT

The Australian stock market fell 0.6 percent on Wednesday August 13, 2025, with the ASX200 down 53.7 points to 8,827.1 points.

Seventeen of the Biotech Daily Top 40 companies were up, 17 fell, five traded unchanged and one was untraded. The four Big Caps were mixed.

Starpharma was the best on no news, up three cents or 26.1 percent to 14.5 cents, with 2.55 million shares traded. Avita climbed 13.8 percent; 4D Medical was up 8.9 percent; Imugene improved 7.55 percent; Paradigm was up 6.8 percent; Atomo, Clarity and Cynata were up more than five percent; Alcidion was up 4.55 percent; EBR and Nova Eye were up three percent or more; Clinuvel, CSL, Prescient and Telix rose two percent or more; Aroa and Mesoblast were up more than one percent; with Cochlear and Orthocell up by less than one percent.

Yesterday's 14.3 percent best, Universal Biosensors, led the falls, down 0.3 cents or 12.5 percent to 2.1 cents, with 2.6 million shares traded. Curvebeam, Genetic Signatures and Impedimed fell four percent or more; Botanix, Immutep, Optiscan and Syntara lost more than three percent; Amplia, Emvision, Neuren, Proteomics and Pro Medicus shed two percent or more; Compumedics, Cyclopharm, Medical Developments, Micro-X and Resmed were down one percent or more; with Polynovo down by 0.9 percent.

AVITA MEDICAL

Avita says it has raised $22,706,489, at $1.32 per Chess depository interest (CDI) in a placement to institutional and professional investors.
Avita said the issue price was an 11 percent discount to the last closing price of $1.48 per CDI, with the securities to be issued under its available placement capacity.
The company said the funds would be used for working capital, and "additional strategic flexibility to support continued growth of the company's therapeutic acute wound portfolio".
Avita said MST Financial Services was sole lead manager to the placement.
Avita was up 20.5 cents or 13.8 percent to $1.69 with 1.4 million shares traded.

ATOMO DIAGNOSTICS

Atomo says it has placed the remaining $416,612 shortfall from its share purchase plan at 1.85 cents a share, taking the total raised with the placement to $3,113,000.
Last month, Atomo said it raised $2,113,000 in a placement at 1.85 cents a share and $272,388 of a hoped-for $1.0 million in a share purchase plan, leaving a $727,612.50 shortfall and taking the total raised to $2,385,388 (BD: Jun 27, 2025).
Later, the company said it had placed $260,000 of the $727,613 share plan shortfall, taking the total raised to $2,645,388 (BD: Jul 21, 2025).
Today, Atomo managing-director John Kelly said the company had an additional $51,000 included in the $260,000 raised on July 21, 2025, taking the total to $311,000.
The company said the shortfall was placed "after receiving inbound interest from institutional and sophisticated investors following Atomo's recent announcement of an order from Lumos for Atomo's Pascal cassettes" (BD: Aug 7, 2025).
Atomo said the shortfall investors would receive one option for every share issued, exercisable at four cents each by August 14, 2028.
The company said Bay Financial and GBA Capital were the shortfall joint lead managers.
Atomo was up 0.1 cents or 5.6 percent to 1.9 cents with 2.6 million shares traded.

ORTHOCELL

Orthocell says 10 surgeries using its Remplir nerve repair product have been conducted in the US, with commercialization continuing as planned.
Earlier this year, Orthocell said it had US Food and Drug Administration 510(k) clearance to begin commercial distribution of Remplir (BD: Apr 4, 2025).
Later, the company said the first US commercial surgery using its Remplir collagen membrane-based nerve repair product was completed; and last month, said it had recorded its first US sales revenue from Remplir (BD: Jun 27, Jul 10, 2025).
Today, Orthocell said it had lodged 36 applications to hospital value assessment committees (VACs), with three approvals received.
The company said VACs reviewed requests for the use of products, services, or technologies in hospitals, assessing clinical effectiveness, safety, and cost.
Orthocell said it had shipped 4,000 Remplir units to its US logistics provider for use in US surgical procedures, with all units manufactured at its Western Australia factory.
The company said it had hired a US regional sales director and an additional on-the ground employee in the US to support commercialization.
Orthocell managing-director Paul Anderson said the company continued "to make excellent progress in the US with surgeons building familiarity through early surgical procedures".
Orthocell was up one cent or 0.8 percent to $1.24 with 871,184 shares traded.

VITASORA HEALTH (FORMERLY RESPIRI)

Vitasora says with Florida's Tampa Family Health Centers it will provide chronic care management and remote patient monitoring (RPM) for Medicaid patients.
Vitasora said Tampa Family Health Center had more than about 7,000 Medicaid patients to be enrolled, generating about $US4,000,000 ($A6,128,000) in annual revenue.
The company said Tampa Family Health Center operated more than 23 clinics, more than 114,000 patients and 42 percent, or about 48,000, were Medicaid patients.
Vitasora said that about 20,000 of the Tampa Family Health's Medicaid patients were eligible for chronic care management and remote patient monitoring services under current US Centers for Medicare and Medicaid Services guidelines.
The company said fee-for-serve rates would range from $US35 to $US90 per patient per month, depending on the level of care provided.
Vitasora said the contract had an initial term of one year, with automatic annual renewal unless either party provided notice of termination, the program was expected to be ready within 30 days, with the first Medicaid patients enrolled from mid-September and initial revenues in the following 30 to 60 days.
Vitasora managing-director Marjan Mikel said the company was "proud to expand our partnership with Tampa Family Health Centers, a nationally respected leader in community healthcare".
"This initiative reflects our shared belief that high-quality, digitally enabled care should be accessible to all Americans," Mr Mikel said.
"It's a significant step forward in delivering real, universal impact at scale," Mr Mikel said.
Vitasora was unchanged at 2.6 cents with 5.8 million shares traded.

IMAGION BIOSYSTEMS

Imagion says with Detroit, Michigan's Wayne State University it will develop an artificial intelligence (A.I.) for use with its Magsense imaging agent for cancer diagnostics.
Imagion said the research would determine the lowest dose of Magsense for detection sensitivity and establish magnetic resonance imaging (MRI) protocols for Magsense.
The company said it would collaborate with Siemens to transfer the protocols to its phase II clinical trial sites and employ imaging techniques that could yield A.I. comparable data.
In July, Imagion said it expected to file a US Food and Drug Administration investigational new drug application (IND) for a phase II trial of Magsense for breast cancer by October (BD: Jul 15, 2025).
Today, Imagion said Wayne State's Dr Mark Haacke and Dr Sagar Bush "pioneered the use of MRI in quantitative imaging" and had a long-standing relationship with Siemens.
The company said that Dr Haacke had been "a pioneer in quantitative MRI for decades, and the collaboration with his team will lay the foundation for future automated analysis of Magsense images using A.I.".
"By implementing quantitative [MRI] techniques, the specific signature of Magsense imaging agents will be uniquely detectable in affected tissue," Imagion said.
Imagion said that "by combining advanced quantitative imaging with the Magsense imaging agents the company aims to enable A.I.-based interpretation and to deliver more accurate and precise data for cancer detection and patient care".
Imagion chief business officer Ward Detwiler said that combining the University's "knowledge and expertise in quantitative MRI, with the specificity of our targeted Magsense imaging agents, we believe we can significantly improve the diagnostic utility of the images by introducing quantitative data to enable precise, A.I.-based detection".
Imagion was unchanged at 1.5 cents with 1.25 million shares traded.

LUMOS DIAGNOSTICS HOLDINGS

Lumos says it has an ASX Listing Rule 10.1 waiver allowing it to grant “a first-ranking general security over its assets” without shareholder approval for a $5 million loan.
According to the ASX, Listing Rule 10.1 says an entity must not acquire or dispose of a substantial asset to persons including a related party or a person who was or is, at any time in the six months prior to the transaction a substantial holder, without shareholder approval.
Lumos said the waiver was a condition of its $5 million loan facility with Perth’s Tenmile and Sydney’s Ryder Capital, who were providing 50 percent of the funds, each.
Last year, Ryder Capital said it held 17.0 percent of Lumos; and later, Tenmile, Tattarang, Nicola and Dr Andrew Forrest said they held 19.9 percent (BD: Oct 10, 11, 2024).
Last month, Lumos said it had a $5.0 million loan from Dr Andrew Forrest’s Tenmile Ventures and Ryder Capital prior to a US Febridx approval (BD: Jul 17, 2025).
Today, the company said the “first-ranking general security” would be granted upon execution of a definitive binding agreement for the loan, without shareholder approval.
Lumos fell 0.4 cents or 4.1 percent to 9.4 cents with 6.4 million shares traded.

FIREBRICK PHARMA

Firebrick says the European Patent Office has accepted a patent protecting its Nasodine nasal spray for Covid-19.
Firebrick said the patent, titled ‘Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes’ would protect its intellectual property until 2040.
The company said the patent protected the use of Nasodine and any other intranasal povidone-iodine preparations as a method of reducing the viral load of Sars-Cov-2 in the nose, as well as pre-exposure prophylaxis, or preventative use prior to exposure, notably in the case of healthcare workers.
Firebrick said the patent had been granted in the US, Mexico, Australia and South Africa, with applications in other countries pending.
The company said the patent would “proceed to a national validation process under which up-to 38 participating countries in Europe will also grant the patent”.
Firebrick fell 0.1 cents or 1.25 percent to 7.9 cents.

NYRADA INC

Nyrada says it has appointed Prof William Chan as a consultant cardiologist for its phase IIa trial of Xolatryp, or NYR-BI03, for acute myocardial infarction, or heart attack.
Last month, Nyrada said it planned a 150-patient, double-blind, placebo-controlled, randomized, phase IIa trial of Xolatryp for myocardial infarction (BD: Jul 23, 2025).
Today, the company said Prof Chan was a professor at the University of Melbourne and lecturer at Monash University and held public clinical appointments at Western Health and the Alfred Hospital, with affiliation to the Baker Heart and Diabetes Institute.
Nyrada said Prof Chan would provide medical oversight for the study.
Nyrada was up half a cent or 1.7 percent to 30 cents.